Seeking Alpha

PARD
Poniard Pharmaceuticals, Inc.

5/26/2012, 5:36 PM ET
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
PARD Market Currents more »
  • February 3, 2010 Shares of Poniard Pharmaceuticals (PARD) -8.8% after the firm said it's replacing its CEO and cutting its work force by 57%. Moves come after disappointing results last week from a Phase II trial of its cancer drug picoplatin. Shares are down 76% over the past three months.
    Comment!
PARD in Focus more »
PARD News more »
PARD Cramer more »
Currently, there are no Cramer articles on PARD.
PARD Instablog posts more »
  • How to Spot a Short Biotech Opportunity, Part III
    Mon, Jun 7, 2010 • Douglas Krohn • 2 Comments
  • Companies Presenting Data at ASCO
    Thu, May 27, 2010 • Andrew Nava • Comment!
  • Biotech Stocks - Beware of The Covered Call Trap
    Wed, Nov 25, 2009 • Ivan Mutaftchiev • Comment!
  • RxNews Recap for Tuesday 11-17-09
    Wed, Nov 18, 2009 • M. E. Garza • Comment!
  • Cancer Drug missed goal in trial: Down 75% on the day on 33M shares traded
    Mon, Nov 16, 2009 • World Market Media • Comment!
Write a post on PARD
PARD StockTalks
PARD vs. ETF Alternatives
Company Description

We are a Washington corporation that was originally incorporated as NeoRx Corporation in 1984. We changed our name to Poniard Pharmaceuticals, Inc. in June 2006 and relocated our corporate headquarters from Seattle, WA to South San Francisco, CA in September 2006. Our principal executive office... More

Sector: Healthcare
Industry: Biotechnology
Country: United States